Clinical Trial Update: Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on prevention of acute graft-versus-host disease in patients receiving allogeneic ApoGraft stem cell transplantation (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancies

Drugs mentioned

• ApoGraft

Snippet

Sponsor: Cellect Biotechnology | Conditions: Hematological Malignancies | Phase 1, Phase 2 | Status: UNKNOWN